Keisuke Tomii

9.1k total citations
222 papers, 4.0k citations indexed

About

Keisuke Tomii is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Keisuke Tomii has authored 222 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Pulmonary and Respiratory Medicine, 79 papers in Oncology and 52 papers in Epidemiology. Recurrent topics in Keisuke Tomii's work include Lung Cancer Treatments and Mutations (72 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (38 papers) and Lung Cancer Research Studies (37 papers). Keisuke Tomii is often cited by papers focused on Lung Cancer Treatments and Mutations (72 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (38 papers) and Lung Cancer Research Studies (37 papers). Keisuke Tomii collaborates with scholars based in Japan, United States and Australia. Keisuke Tomii's co-authors include Kazuma Nagata, Daichi Fujimoto, Atsushi Nakagawa, Yukihiro Imai, Kojiro Otsuka, Ryo Tachikawa, Nobuyuki Katakami, Takeshi Morimoto, Yuki Sato and Akito Hata and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Keisuke Tomii

217 papers receiving 3.9k citations

Peers

Countries citing papers authored by Keisuke Tomii

Since Specialization

Citations

This map shows the geographic impact of Keisuke Tomii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keisuke Tomii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keisuke Tomii more than expected).

Fields of papers citing papers by Keisuke Tomii

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keisuke Tomii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keisuke Tomii. The network helps show where Keisuke Tomii may publish in the future.

Co-authorship network of co-authors of Keisuke Tomii

This figure shows the co-authorship network connecting the top 25 collaborators of Keisuke Tomii. A scholar is included among the top collaborators of Keisuke Tomii based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keisuke Tomii. Keisuke Tomii is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical outcomes, safety, and potential prognostic factors of noninvasive respiratory support in patients with COVID-19: A Japanese multicenter observational study 2025 ·Respiratory Investigation ·Jiro Ito, Toshiki Yokoyama, Aiko Tanaka, Ryutaro Seo, Keisuke Tomii, (unknown), Shinyu Izumi, Yutaka Kozu, Kazuo Chin, (unknown), Naoki Nishimura, Hajime Sasano, Kazuko Yamamoto, (unknown), (unknown), Motoo Yamauchi, Tetsuhisa Kitamura, Yuji Fujino, Yasuhiro Kondoh	0
2	Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia 2024 ·ERJ Open Research ·Kazutoshi Isobe, Yasuhiko Nakamura, Susumu Sakamoto, Keisuke Tomii, Takayuki Takimoto, Yasunari Miyazaki, Masaru Matsumoto, Keishi Sugino, Kazuya Ichikado, (unknown), Kakuhiro Yamaguchi, Tomohisa Baba, Hiroaki Ozasa, (unknown), (unknown), Sakae Homma, Hiroshi Date, Takafumi Suda, Kazuma Kishi	4
3	Risk stratification and prognosis prediction using cardiac biomarkers in COVID-19: a single-centre retrospective cohort study 2024 ·BMJ Open ·(unknown), (unknown), Takeshi Morimoto, (unknown), (unknown), Ryosuke Murai, (unknown), Yasuhiro Sasaki, Tomohiko Taniguchi, Kitae Kim, Atsushi Kobori, Natsuhiko Ehara, Makoto Kinoshita, Asako Doi, Keisuke Tomii, Yasuki Kihara, Yutaka Furukawa	1
4	Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib 2024 ·Thoracic Cancer ·Yuki Sato, (unknown), (unknown), Kei Irie, Shigeki Nanjo, Shigeo Hara, Satoru Fujiwara, Keisuke Tomii	1
5	Management of alveolar‐pleural fistula secondary to invasive pulmonary aspergillosis with bronchial occlusion using a combination of Endobronchial Watanabe Spigot and N‐butyl‐2‐cyanoacrylate: A case report 2023 ·SHILAP Revista de lepidopterología ·(unknown), Kazuma Nagata, Keisuke Tomii	1
6	Mechanical ventilation for acute exacerbation of fibrosing interstitial lung diseases 2023 ·Respiratory Investigation ·(unknown), Kazuma Nagata, Takeshi Morimoto, Keisuke Tomii	4
7	Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis 2023 ·Respiratory Investigation ·Yasuhiko Nishioka, Sakae Homma, Takashi Ogura, Seidai Sato, (unknown), Keisuke Tomii, Koichiro Kamio, Susumu Sakamoto, Yasunari Miyazaki, Hiromi Tomioka, Shu Hisata, Tomohiro Handa, Arata Azuma	7
8	A pseudo-outbreak of COVID-19 associated pulmonary aspergillosis: a microbiological investigation of both the patients and the environment 2023 ·Journal of Infection Prevention ·(unknown), Asako Doi, (unknown), (unknown), (unknown), (unknown), Hiroaki Nishioka, Keisuke Tomii	1
9	Prognostic Value of Computed Tomography in Empyema: A Multicenter Retrospective Cohort Study 2023 ·Annals of the American Thoracic Society ·Akihiro Shiroshita, (unknown), (unknown), (unknown), Yue Cong, (unknown), Keisuke Anan, Kenya Sato, (unknown), Masafumi Takeshita, (unknown), (unknown), Hiroyuki Suzuki, (unknown), Jun Suzuki, Keisuke Tomii, (unknown), Yuki Kataoka	5
10	SARS-CoV-2 ORF8 is a viral cytokine regulating immune responses 2022 ·International Immunology ·Masako Kohyama, Tatsuya Suzuki, Wataru Nakai, Chikako Ono, Sumiko Matsuoka, (unknown), Yafei Liu, Yusuke Sakai, (unknown), Keisuke Tomii, Koichiro Ohmura, Masato Okada, Yoshiharu Matsuura, Shiro Ohshima, Yusuke Maeda, Toru Okamoto, Hisashi Arase	12
11	Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study 2021 ·Clinical Epidemiology and Global Health ·Asako Doi, Kentaro Iwata, (unknown), (unknown), (unknown), (unknown), (unknown), Hiroaki Nishioka, Keisuke Tomii, Takeshi Morimoto, Yasuki Kihara	27
12	Effect of high‐flow nasal cannula oxygen therapy on exercise tolerance in patients with idiopathic pulmonary fibrosis: A randomized crossover trial 2021 ·Respirology ·(unknown), Kazuma Nagata, Takeshi Morimoto, K. Iwata, (unknown), Yuki Sato, Ryo Tachikawa, Akira Ishikawa, Keisuke Tomii	22
13	Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases 2021 ·Supportive Care in Cancer ·Hiroaki Ikesue, (unknown), Hideaki Tomita, (unknown), (unknown), Nobuyuki Muroi, Shinsuke Yamamoto, Toshihiko Takenobu, Keisuke Tomii, Mutsushi Kawakita, Hironori Katoh, Takayuki Ishikawa, Hisateru Yasui, Tohru Hashida	27
14	Predicting in-hospital death in pneumonic COPD exacerbation via BAP-65, CURB-65 and machine learning 2021 ·ERJ Open Research ·Akihiro Shiroshita, (unknown), (unknown), (unknown), Kenya Sato, Shin-ya Matsushita, Keisuke Tomii, Yuki Kataoka	8
15	Effectiveness of empirical anti-pseudomonal antibiotics for recurrent COPD exacerbation: a multicenter retrospective cohort study 2021 ·Scientific Reports ·Akihiro Shiroshita, Chisato Miyakoshi, (unknown), (unknown), (unknown), Kenya Sato, (unknown), (unknown), Keisuke Tomii, (unknown), Yuki Kataoka	3
16	The prognostic factors of in-hospital death among patients with pneumonic COPD acute exacerbation 2021 ·Respiratory Investigation ·(unknown), Akihiro Shiroshita, (unknown), Kenya Sato, (unknown), Keisuke Tomii, Yuki Kataoka	3
17	PHARMACOKINETICS OF FAVIPIRAVIR IN CRITICALLY ILL PATIENTS WITH COVID-19 2021 ·Clinical Pharmacology & Therapeutics ·Keiichi Irie, (unknown), Hiroaki Fujita, (unknown), Masato Eto, (unknown), (unknown), Keisuke Tomii, Tohru Hashida	6
18	Evaluation of the usefulness of protocol‐based pharmacist‐facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer 2020 ·Journal of Clinical Pharmacy and Therapeutics ·Hiroaki Ikesue, (unknown), (unknown), (unknown), (unknown), Yoshio Masuda, (unknown), Nobuyuki Muroi, Daichi Fujimoto, Takeshi Morimoto, Keisuke Tomii, Tohru Hashida	7
19	Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report 2018 ·Investigational New Drugs ·(unknown), Daichi Fujimoto, (unknown), (unknown), Keisuke Tomii	13
20	Two cases of fatal adrenal hemorrhage secondary to metastatic lung cancer. 1990 ·Haigan ·Keisuke Tomii, Yoshio Taguchi, (unknown), (unknown), Akira Sano, Yasumasa Kuroda	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact